Immunophenotypic Landscape and Prognosis of Diffuse Large B-Cell Lymphoma with MYC/BCL2 Double Expression: An Analysis of A Prospectively Immunoprofiled Cohort.

ABSTRACT: Diffuse large B-cell lymphoma (DLBCL) patients with MYC/BCL2 double expression (DE) show poor prognosis and their clinical outcomes after R-CHOP therapy vary immensely. We investigated the prognostic value of DE in aggressive B-cell lymphoma patients (n = 461), including those with DLBCL (n = 417) and high-grade B-cell lymphoma (HGBL; n = 44), in a prospectively immunoprofiled cohort. DE was observed in 27.8% of DLBCLs and 43.2% of HGBLs (P = 0.058). DE-DLBCL patients were older (P = 0.040) and more frequently exhibited elevated serum LDH levels (P = 0.002), higher international prognostic index (IPI; P = 0.042), non-germinal-center B-cell phenotype (P < 0.001), and poor response to therapy (P = 0.042) compared to non-DE-DLBCL patients. In R-CHOP-treated DLBCL patients, DE status predicted

SUBMITTER: Han B 

PROVIDER: S-EPMC7697982 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature